Since the discovery of the human immunodeficiency virus (HIV) in the early 1980s, it has been a significant global public health concern. This terrible virus has claimed millions of lives and continues to affect individuals across the globe. HIV belongs to the retrovirus family and specifically the lentivirus sub-group, attacking the immune system and leading to acquired immunodeficiency syndrome (AIDS). The virus is renowned for its high variability, posing significant challenges to treatment and prevention through evolution (Campestrini et al., 2018).

It is estimated that approximately 38 million people are infected with HIV globally, making the epidemic a pressing global health concern. The virus is primarily transmitted through unprotected sexual behavior, shared contaminated needles, and mother-to-child during pregnancy, delivery, or breastfeeding (Ishay et al., 2020). Despite significant advancements in antiretroviral therapy (ART) in recent years, there is still no cure for HIV. Management of HIV infection focuses on suppressing viral replication, delaying disease progression, and reducing transmission risks (Kesby et al., 2018). However, the emergence of drug resistance and an increase in viral strain diversity pose significant challenges to effective treatment and prevention.

It is evident that a deeper understanding of the interplay between HIV variants and host antibody responses is crucial. Understanding how virus variants impact the immune system and how host antibodies respond to these variants can provide a better understanding of HIV pathogenesis and viral escape mechanisms. In-depth research on virus variants and antibody responses can provide novel insights and targets for vaccine and antiviral treatment strategies (Cassandra et al., 2019).

The primary aim of this study is to review the interplay between HIV variants and host antibody responses, exploring its significance in virus control and disease prevention. The study will analyze the mechanisms and influencing factors of HIV variants, describe the interactive mechanisms of virus escape and antibody responses, and discuss the application of existing research methods and technologies in addressing this issue. The findings will contribute to enhancing our understanding of HIV infection, its treatment, and prevention, providing scientific evidence for future research and intervention development.

1 Important Variant Types of HIV Virus

1.1 Basic concepts of mutation and evolution

HIV is an RNA virus whose genome consists of RNA molecules instead of the more common DNA (Figure 1). It is the causative agent of AIDS. The virus is transmitted through blood, sexual contact, or mother-to-child during pregnancy, delivery, or breastfeeding. HIV infection mainly attacks the body's immune system, particularly CD4+ T lymphocytes, disrupting the function of the immune system. As a result, the patient's immune system becomes fragile and vulnerable to other infections and diseases. HIV is classified into multiple subtypes and serotypes based on differences between different regions and individuals. The most common ones are HIV-1 and HIV-2. HIV-1 is the most prevalent subtype globally, while HIV-2 is prevalent mainly in West Africa. HIV has a high degree of variability, which means it can produce different mutations in infected individuals and between populations (Robert et al., 2019). This variability can affect the effectiveness of vaccine development and antiviral treatment strategies. HIV mutation and evolution refers to the changes and accumulation of genetic information produced by the HIV genome during replication. Due to the high error rate during HIV replication, new mutant strains are generated. This high variability is one of the important reasons why HIV can evade the host immune system and antiviral drugs (Han et al., 2021).

HIV mutations are mainly caused by the error replication of its reverse transcriptase. Reverse transcriptase is an enzyme that converts the virus's RNA into DNA and integrates it into the host cell's chromosomes. However, reverse transcriptase is prone to making mistakes during replication, leading to mutations in the newborn virus genome (Figure 1). These mutations can be point mutations, where a single nucleotide changes, or insertions or deletions, where nucleotides are added or deleted. These mutations lead to changes in the HIV genome and the emergence of various subtypes and strains (Inciarte et al., 2020).

HIV evolution occurs when mutations accumulate and selection pressures shape new virus strains in different environments and hosts. Selection pressures can come from the host immune system and antiviral drug applications. When the host immune system produces antibodies against the virus, pressure urges the virus to change the structure of its surface proteins to evade antibody recognition. This antibody escape mechanism leads to mutations in the virus and confers immune evasion. Similarly, antiviral drug use selects for virus strains with reduced drug sensitivity, leading to drug resistance.

1.2 Cause and mechanism of virus mutation

The reasons and mechanisms of HIV mutation include the high error rate of reverse transcriptase, rapid reproduction and replication, as well as selection pressure and cross-infection. Reverse transcriptase is a key enzyme in the replication process of HIV, responsible for converting the virus's RNA into DNA. However, reverse transcriptase has a high error rate, which means mutations can occur during each replication process. These mutations can lead to errors or deletions in the genome, thereby affecting the survival and replication of the virus.

HIV has the ability to rapidly reproduce and replicate, producing billions of virus particles every day. During this rapid replication process, viruses often experience replication errors. The accumulation of these errors due to the large number of viruses leads to frequent mutations. These mutations can be point mutations (changes in a single base pair), insertions or deletions (insertion or deletion of DNA fragments), or gene recombination (exchange of genes between different HIV strains).

Selection pressure and cross-infection are also important factors in HIV mutation. The attack by the host immune system on the virus creates selection pressure, selecting for those mutant strains that can evade immune responses. These mutant strains gradually become dominant in the population, ultimately leading to immune escape. When different HIV strains infect the same host, their genomes can undergo recombination, forming new mutant virus strains. These mutations and variations make HIV complex and diverse, with the ability to evade the immune system and antiviral drugs. This poses a significant challenge to the treatment and prevention of the disease, and requires research and efforts to find effective strategies to combat HIV.

1.3 The impact of mutations on viruses

Mutations have various impacts on HIV. Mutations make HIV highly variable, which means there is a large genetic difference between virus strains. This variability poses difficulties for antiviral treatment and vaccine development, as a specific drug or vaccine may be effective against one virus strain but not another. Mutations also lead to the development of drug resistance, rendering previously effective drugs ineffective.

Mutations allow HIV to evade recognition and attack by the host immune system. Viral mutations can lead to changes in the structure of surface proteins (such as the HIV envelope protein gp120), enabling the virus to evade antibodies produced by the host. This antibody evasion mutation makes it difficult for the immune system to effectively fight the virus, increasing the severity and progression of the disease.

Mutations can also affect the virulence and transmissibility of HIV. Some mutations may increase the infectiousness of the virus, making it more likely to spread through sexual or blood transmission to others. Mutations can also affect the replication rate and efficiency of the virus, thereby affecting its pathogenic potential and course of the disease.

2 Interaction between Host Antibody Response and AIDS Virus

2.1 Response mechanism of host immune system to AIDS virus infection

The host immune system plays a crucial role in the response to HIV infection, and it employs multiple mechanisms to counteract the virus's attack. Firstly, the host immune system identifies and attacks cells infected with HIV. After infection, the virus releases some viral proteins that can be recognized as "foreign invaders" by immune system cells. The immune system tags these infected cells and destroys them through immune cells such as cytotoxic T cells (Mueller et al., 2018) (Figure 2).

To combat HIV, the host immune system produces specific antibodies. After infection, the immune system activates B cells and prompts them to produce specific antibodies. These antibodies can recognize and bind to the surface proteins of the virus, thereby preventing further infection of host cells and prompting immune cells to clear the virus that is marked by antibodies. The host immune system can regulate and control immune responses through the production of cytokines. Cytokines are secreted proteins that serve as signals and regulators between immune cells. In HIV infection, the production of certain cytokines is modulated, thereby affecting the activity and efficacy of immune cells (van Zyl et al., 2018) (Figure 2).

However, HIV has multiple mechanisms to evade the host immune response. The virus can change the structure of its surface proteins through diversity mutations and recombination, thereby avoiding recognition and attack by antibodies. Additionally, the virus can suppress the activity of the host immune system, disrupt the function of immune cells, or inhibit cytokine production. These evasion mechanisms make the host immune response to HIV infection complex and difficult, providing opportunities for sustained infection and immune escape by the virus.

2.2 Antibody structure and function

Antibodies are a type of protein produced by the immune system, also known as immunoglobulins. Antibodies have a specific structure and function that play an important role in defending against infections and protecting the body from pathogenic invasion. The structure of antibodies is highly unique, typically consisting of two heavy chains and two light chains that form a Y-shaped molecule. They are connected together by disulfide bonds at their C-terminal ends. Each antibody has specificity due to the distinct amino acid sequence of its variable region (hypervariable region), which allows it to recognize and bind to a specific antigen. The variable region of antibodies is generated by genetic recombination and mutation, providing diversity that enables recognition and binding to various antigens (Sanchez et al., 2018).

The function of antibodies is mainly manifested in two aspects. First, antibodies can directly neutralize the toxins or antigens of pathogens, preventing them from entering or invading host cells. When antibodies bind to a pathogen, they can block its attachment to host cells, thereby preventing invasion and damage. Second, antibodies can enhance the immune response of the body by activating other components of the immune system. This includes activating the complement system, inducing inflammatory responses through cytotoxic functions, and promoting the destruction and clearance of antigens by other immune cells.

Antibodies also have other functions, such as regulating immune responses and mediating the activity of immune cells. They can interact with specific immune cells, such as macrophages, NK cells, and other immune cells, thereby regulating the activity and response of the host immune system. These functions make antibodies play a crucial role in various aspects of immune responses.

2.3 The impact of virus mutation on the recognition and binding ability of antibodies

The high variability of HIV has a significant impact on the recognition and binding ability of antibodies, posing a significant challenge in the development of broad-spectrum, high-affinity antibody-based drugs and vaccines. The genetic material of HIV, RNA, undergoes frequent mutations and recombinations, leading to the emergence of a wide range of subtypes and variant strains within the virus population. This variability enables the virus to evade attack by the host immune system, including antibody recognition and binding (Teresa et al., 2019).

Antibodies recognize antigens on the surface of pathogens through their specific structure, with variable regions that have specific amino acid sequences capable of binding to specific areas on the surface of the pathogen. However, due to the variability of HIV, the antigenic epitopes on the surface of the virus can undergo changes, leading to mutations or the disappearance of regions that were previously bound by antibodies. These changes in antigenic epitopes can render antibodies unable to recognize and bind to the virus as the antigenic targets have been altered. This variability can occur in surface proteins of the virus (such as the Env protein of HIV) or other key proteins that play a critical role in the binding process of antibodies.

The variability of HIV also leads to the emergence of multiple subtypes and variant strains with distinct epitope and structural characteristics. This makes it challenging for a single antibody to cover all subtypes and variant strains as antibodies can only bind to specific antigens. Therefore, an antibody may have strong binding capacity for one subtype or variant strain but may be ineffective against other subtypes or variant strains.

3 The Consequences of Antibody Escape Mutation and Viral Infection

3.1 The definition and mechanism of antibody escape mutation

Antibody escape mutation refers to the ability of HIV, due to its high degree of variability and high replication rate, to produce mutations that allow the virus to evade attack by the host immune system's antibodies during infection. This mutation enables the virus to avoid antibody recognition and binding, thereby protecting itself from immune system attacks (Liu et al., 2019).

The mechanisms of antibody escape mutation mainly include point mutations and structural changes. Point mutations refer to changes in individual nucleotides in the viral genome, leading to changes in the antigenic epitopes recognized by antibodies. These mutations may alter the structure, charge, or affinity of epitopes, making it difficult for antibodies to effectively bind. The virus can also weaken or prevent antibody binding by changing the amino acid sequence surrounding the antibody binding site (Montoya et al., 2018).

Structural changes refer to the structural modifications of epitopes through mechanisms such as deletion, insertion, or rearrangement during infection. These changes can alter the structure and affinity of antibodies for the virus, making antibodies lose their specificity for the epitopes recognized by the original antibodies. Antibody escape mutation plays a crucial role in HIV transmission and viral replication. This mutation allows the virus to evade host immune system surveillance, establish persistent infection in hosts, and lead to further virus transmission and development. Given the antigenic variability of HIV, developing broad-spectrum antibody-based drugs and vaccines that target different subtypes and variant strains remains a challenge.

3.2 The impact of antibody escape mutation on viral infection

Due to the high degree of virus variability and the existence of escape mechanisms, antibody escape mutation enables the virus to effectively evade the host immune system's antibody attack, thereby increasing the persistence and replicative capacity of the virus infection. Antibody escape mutation allows the virus to avoid being quickly cleared by antibodies. When the virus enters the host, the immune system produces specific antibodies to recognize and bind to virus particles, thereby neutralizing or marking the virus for clearance by the host immune system. However, HIV has developed new antigenic epitopes through mutation, avoiding specific antibody binding and making it difficult for the host immune system to effectively clear the infection. This allows the virus to persist and replicate within the host.

Antibody escape mutation also leads to the development of drug resistance in the virus. During antiviral treatment, selective pressure can guide the virus to develop drug-resistant mutations, making previously sensitive antiviral drugs ineffective in inhibiting virus replication. This drug resistance often involves mutations in antigenic epitopes involved in virus infection, making it impossible for antibodies to continue binding to the virus and rendering antiviral drugs ineffective.

3.3 The challenges of antibody escape mutation in vaccine development

Antibody escape mutation undoubtedly poses a great challenge to HIV vaccine development. Due to the high genetic variability of HIV, the virus not only exists in multiple subtypes, but also has a large number of variant strains within the same subtype. This leads to the emergence of antibody escape mutation, making it difficult for vaccines targeting specific antigenic epitopes to provide broad protection (Ivan et al., 2018).

Antibody escape mutation renders vaccines targeting specific epitopes ineffective. Vaccines typically stimulate the immune system to produce specific antibodies to prevent virus infection. However, due to the variability of HIV, vaccines may only induce the production of antibodies targeting the epitopes of the original virus strain. These antibodies may not recognize and neutralize newly emerging variant strains, thus failing to provide broad protection. Antibody escape mutation also brings the problem of virus escape from immune response. The variant virus strains may adopt different epitope structures, making it difficult for the immune system to recognize and attack them (Michael et al., 2019). Such escape mutations may lead to partial or complete failure of vaccine-induced immune responses, rendering the vaccine ineffective in inhibiting virus infection.

The replication and infection process of HIV is dynamic, with the virus continuously undergoing mutation and evolution in the body. This means that even if a vaccine can effectively inhibit the current virus variant strains, its long-term effectiveness cannot be guaranteed. Antibody escape mutation poses a significant challenge for vaccines in coping with the continuous changes of the virus.

To overcome these challenges, researchers are exploring different strategies. One approach is to develop broad-spectrum vaccines that contain antigenic epitopes from multiple HIV strains in the hope of inducing a broader antibody response. Another approach is to study and utilize highly conserved regions of non-structural proteins in order to reduce the possibility of virus escape mutations.

3.4 Actual cases of antibody escape mutation

Antibody escape mutation refers to the mutations that occur in the interaction between HIV and antibodies in the host immune system, enabling virus strains that were originally recognized and neutralized by antibodies to evade immune attack. This phenomenon poses a challenge to vaccine development, as vaccines need to effectively induce the production of specific antibodies to combat the virus (Pragna et al., 2018). Here are some actual cases:

VRC01 antibody and HIV-1 escape mutation. VRC01 is a broad-spectrum neutralizing antibody that can neutralize most HIV-1 strains. However, some HIV-1 strains have mutated to evade binding and neutralization by VRC01, especially in the CD4 binding region of the virus.

PG9 antibody and HIV-1 escape mutation. PG9 is a highly specific neutralizing antibody that can neutralize some HIV-1 strains. However, some HIV-1 strains have changed their glycosylation structure to evade binding by PG9, reducing its neutralization effect.

3BNC117 antibody and HIV-1 escape mutation. 3BNC117 is another broad-spectrum neutralizing antibody that neutralizes HIV-1 by binding to the outer membrane protein gp120 of the virus. However, some HIV-1 strains can evade neutralization by 3BNC117 by changing the structure of gp120.

These cases demonstrate the variability of HIV and the challenges of antibody escape mutation to the development of antibody-based vaccines. To overcome these challenges, researchers are working on developing new vaccine strategies, such as designing multivalent vaccines, combining multiple neutralizing antibodies, and utilizing other immune mechanisms to improve vaccine efficacy.

4 Summary and Outlook

The high variability of HIV poses challenges to host antibodies in clearing the virus, while selective pressure from host antibodies prompts the virus to develop escape mutations to evade antibody attack. Specifically, the antibody escape mutations of the virus enable it to avoid being quickly cleared by antibodies, increasing the persistence and replicative capacity of the virus and leading to the occurrence of drug resistance. This poses challenges to vaccine development, as vaccines targeting specific virus strains may not provide broad protection, and the continuous mutation of the virus threatens the durability of the vaccine.

Future research and applications need to work on addressing the interplay between HIV variation and host antibody responses. This includes in-depth studies of the mechanisms and escape routes of virus variation to better understand the occurrence and evolution of antibody escape mutations. This can help develop new vaccine strategies, including broad-spectrum vaccines and multi-epitope vaccines. Other immune response pathways, such as cell-mediated immune responses, also need to be explored to compensate for the limitations of antibody responses. The combined application of antibodies and antiviral drugs can improve treatment outcomes and reduce the development of drug resistance (Claude et al., 2011). Establishing more detailed dynamic models of virus evolution and antibody responses can help better understand the evolutionary mechanisms of HIV and the processes of antibody production and disappearance. This will provide more comprehensive information and guidance for effective interventions and treatments. Researchers can further explore new therapeutic strategies based on virus variation, such as therapies targeting specific variant strains or multi-target antiviral drugs. At the same time, for existing antiviral drugs, it is necessary to conduct in-depth studies on their impact on drug resistance due to virus variation and develop new drugs to address these challenges. Emphasis should also be placed on studying the mechanisms of early infection and immune escape to facilitate early intervention and treatment.

In-depth research on the interplay between HIV variation and host antibody responses not only helps better understand the transmission and evolutionary mechanisms of HIV, but also provides opportunities for vaccine development and the development of new treatment strategies. Understanding the interplay between HIV variation and host antibody responses is also key to developing effective vaccines and treatment strategies. By studying the mechanisms of virus variation, developing new vaccine strategies, and combining antibodies with antiviral drugs, it is hoped that the challenges posed by antibody escape mutations can be overcome, ultimately leading to effective prevention and treatment of HIV infection.

References

Campestrini J., Silveira D.B., and Pinto A.R., 2018, HIV-1 tat-induced bystander apoptosis in jurkat cells involves unfolded protein responses, Cell Biochemistry and Function, 36(7): 377-386.

https://doi.org/10.1002/cbf.3357

Cassandra S., Anthony R M., Brian W., and Michael R N., 2019, Genetic variation and function of the HIV-1 Tat protein, Medical Microbiology and Immunology, 208: 131-169.

https://doi.org/10.1007/s00430-019-00583-z

Claude A., Katherine T., Kathleen M., Moscicki A.B., Doyle P., Renee S., Ann U., Susannah M.A., Russell V.D., and George R.S., 2011, Behavioral health risks in perinatally HIV-exposed youth: co-occurrence of sexual and drug use behavior, mental health problems, and nonadherence to antiretroviral treatment, AIDS Patient Care and STDs, 25: 7.

https://doi.org/10.1089/apc.2011.0025

Han M.M., Frizzi K.E., Ellis R.J., Calcutt N.A., and Fields J.A., 2021, Prevention of HIV-1 tat protein-induced peripheral neuropathy and mitochondrial disruption by the antimuscarinic pirenzepine, Frontiers Media SA, 33.

https://doi.org/10.3389/fneur.2021.663373

Inciarte A., Anaa G.C., Rojas J., Torres B., de Lazzari E., Mora L., Mariaa M.R., Laguno M., Callau P., Gonzalez N.A., Leal L., Garcia F., Mallolas J., Mosquera M., Marcos M., Ambrosioni J., Miro J.M., Martinez E., and Blanco J.L., 2020, Clinical characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort of adults living with HIV: a single-center, prospective observational study, AIDS, 34(12): 1775-1780.

https://doi.org/10.1097/QAD.0000000000002643

Ishay Y., Kessler A., Schwarts A., and Ilan Y., 2020, Antibody response to severe acute respiratory syndrome- corona virus 2, diagnostic and therapeutic implications, Hepatology Communications, 4(12): 1731-1743.

https://doi.org/10.1002/hep4.1600

Ivan K., Ince W.L., Gentles L.E., Oler A.J., Martina K., Matthew A., Magadán J.G., Hang X., Brooke C.B., and Yewdell J W., 2018, Influenza a virus hemagglutinin glycosylation compensates for antibody escape fitness costs, PLoS Pathogens, 14(1): e1006796.

https://doi.org/10.1371/journal.ppat.1006796

Kesby J.P., Fields J.A., Chang A. , Coban H., Achim C.L., and Semenova S., 2018, Effects of HIV-1 tat protein and methamphetamine exposure on visual discrimination and executive function in mice, Behavioural Brain Research, 349: 73-79.

https://doi.org/10.1016/j.bbr.2018.04.046

Liu X.R., Chen Y., Zhao Y.W., Virginia L.C., Chen W., Payne G., and Alexandru C., 2019, Identification and characterization of co-purifying cho host cell proteins in monoclonal antibody purification process, Journal of Pharmaceutical and Biomedical Analysis, 174: 500-508.

https://doi.org/10.1016/j.jpba.2019.06.021

Michael W.T., Vincent J.C., and Jason A., 2019, Association of HIV preexposure prophylaxis with incidence of sexually transmitted infections among individuals at high risk of HIV infection, JAMA, 321(14): 1380-1390.

https://doi.org/10.1001/jama.2019.2947

Montoya D.J., Andrade P., Silva B., Teles R.M.B., Bryson B.D., Sadanand S., Noel T., Jing L., Sarno E., and Arnvig K., 2018, Dual rnaseq of human leprosy lesions identifies bacterial determinants linked to host immune response, BioRxiv., 10: 11.

https://doi.org/10.1101/354407

Mueller N., Pasternak A.O., Klaver B., Cornelissen M., Berkhout B., and Das A.T., 2018, The HIV-1 tat protein enhances splicing at the major splice donor site, Journal of Virology, 92(14): e01855.

https://doi.org/10.1128/JVI.01855-17

Pragna P., Charles E.R., Pamela Y.C., Bernardo N.B., Vikrant V.S., Emmanuel P., Susan V., Sonak D.P., Dianne R., and Naomi S.L., 2018, Noncommunicable diseases among HIV-infected persons in low-income and middle-income countries: a systematic review and meta-analysis, AIDS, 32(1): 5-20.

https://doi.org/10.1097/QAD.0000000000001888

Robert H.R., Michael J.S., Nadia N., Reuben N.R., Andrea N.P., and Claude A.M., 2019, Mental health and HIV/AIDS: the need for an integrated response, National Library of Medicine, 33(9): 1411-1420.

https://doi.org/10.1097/QAD.0000000000002227

Sanchez H.N., Gan H., Moroney J.B., Daw C.C., Taylor J., Zan H., and Casali P., 2018, B cell-intrinsic epigenetic modulation of local and systemic antibody response by gut microbiota through catabolic short-chain fatty acids, The Journal of Immunology, 200(1): 118.

https://doi.org/10.4049/jimmunol.200.Supp.118.3

Teresa F., Cha S., Xia M., Lindsay T., Damian D., Joseph P., Dafna K., and Cyprian W., 2019, Changes in HIV preexposure prophylaxis awareness and use among men who have sex with men - 20 urban areas, 2014 and 2017, MMWR Morb Mortal Wkly Rep., 68(27): 597-603.

van Zyl G., Bale M.J., and Kearney M.F., 2018, HIV evolution and diversity in ART-treated patients, Retrovirology, 15: 14.

https://doi.org/10.1186/s12977-018-0395-4